Bifogade filer
PDF
Kurs & Likviditet
Kalender
| 2025-02-21 | Bokslutskommuniké 2024 |
| 2024-11-15 | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | Årsstämma 2024 |
| 2024-05-17 | Ordinarie utdelning CLS B 0.00 SEK |
| 2024-05-17 | Kvartalsrapport 2024-Q1 |
| 2024-04-25 | Split CLS B 200:1 |
| 2024-04-12 | Extra Bolagsstämma 2024 |
| 2024-02-23 | Bokslutskommuniké 2023 |
| 2023-11-17 | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | Kvartalsrapport 2023-Q2 |
| 2023-06-29 | Årsstämma 2023 |
| 2023-06-22 | Ordinarie utdelning CLS B 0.00 SEK |
| 2023-06-08 | Extra Bolagsstämma 2023 |
| 2023-05-25 | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | Bokslutskommuniké 2022 |
| 2022-11-22 | Extra Bolagsstämma 2022 |
| 2022-11-17 | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | Kvartalsrapport 2022-Q2 |
| 2022-06-29 | Ordinarie utdelning CLS B 0.00 SEK |
| 2022-06-28 | Årsstämma 2022 |
| 2022-05-19 | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | Bokslutskommuniké 2021 |
| 2021-11-18 | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | Kvartalsrapport 2021-Q2 |
| 2021-06-29 | Ordinarie utdelning CLS B 0.00 SEK |
| 2021-06-28 | Årsstämma 2021 |
| 2021-05-19 | Kvartalsrapport 2021-Q1 |
| 2021-03-31 | Extra Bolagsstämma 2021 |
| 2021-02-26 | Bokslutskommuniké 2020 |
| 2020-11-19 | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2020-06-11 | Årsstämma 2020 |
| 2020-05-28 | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | Bokslutskommuniké 2019 |
| 2019-11-21 | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | Kvartalsrapport 2019-Q2 |
| 2019-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2019-05-17 | Årsstämma 2019 |
| 2019-05-16 | Kvartalsrapport 2019-Q1 |
| 2019-03-18 | Extra Bolagsstämma 2019 |
| 2019-02-14 | Bokslutskommuniké 2018 |
| 2018-11-22 | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | Kvartalsrapport 2018-Q2 |
| 2018-06-20 | Årsstämma 2018 |
| 2018-06-14 | Ordinarie utdelning CLS B 0.00 SEK |
| 2018-05-24 | Kvartalsrapport 2018-Q1 |
| 2018-05-18 | Extra Bolagsstämma 2018 |
| 2018-02-22 | Bokslutskommuniké 2017 |
| 2017-11-16 | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | Kvartalsrapport 2017-Q2 |
| 2017-06-28 | Ordinarie utdelning CLS B 0.00 SEK |
| 2017-06-27 | Årsstämma 2017 |
| 2017-05-18 | Kvartalsrapport 2017-Q1 |
| 2017-01-31 | Bokslutskommuniké 2016 |
| 2017-01-20 | Extra Bolagsstämma 2017 |
| 2016-11-17 | Kvartalsrapport 2016-Q3 |
| 2016-08-18 | Kvartalsrapport 2016-Q2 |
| 2016-06-16 | Årsstämma 2016 |
| 2016-05-19 | Kvartalsrapport 2016-Q1 |
| 2016-02-21 | Bokslutskommuniké 2015 |
| 2015-11-19 | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | Kvartalsrapport 2015-Q2 |
| 2015-06-12 | Ordinarie utdelning CLS B 0.00 SEK |
| 2015-06-11 | Årsstämma 2015 |
| 2015-05-21 | Kvartalsrapport 2015-Q1 |
| 2015-02-23 | Bokslutskommuniké 2014 |
| 2014-11-14 | Kvartalsrapport 2014-Q3 |
| 2014-08-20 | Kvartalsrapport 2014-Q2 |
| 2014-06-18 | Ordinarie utdelning CLS B 0.00 SEK |
| 2014-06-17 | Årsstämma 2014 |
| 2014-05-22 | Kvartalsrapport 2014-Q1 |
| 2014-02-24 | Bokslutskommuniké 2013 |
| 2013-11-22 | Kvartalsrapport 2013-Q3 |
| 2013-09-19 | Extra Bolagsstämma 2013 |
| 2013-08-20 | Kvartalsrapport 2013-Q2 |
| 2013-06-10 | Ordinarie utdelning CLS B 0.00 SEK |
| 2013-06-07 | Årsstämma 2013 |
| 2013-05-24 | Kvartalsrapport 2013-Q1 |
| 2013-02-25 | Bokslutskommuniké 2012 |
| 2012-11-23 | Kvartalsrapport 2012-Q3 |
| 2012-08-24 | Kvartalsrapport 2012-Q2 |
| 2012-06-08 | Ordinarie utdelning CLS B 0.00 SEK |
| 2012-06-07 | Årsstämma 2012 |
| 2012-04-20 | Kvartalsrapport 2012-Q1 |
| 2012-01-09 | Bokslutskommuniké 2011 |
| 2012-01-04 | Extra Bolagsstämma 2012 |
| 2011-11-21 | Kvartalsrapport 2011-Q3 |
| 2011-09-26 | Kapitalmarknadsdag 2010 |
| 2011-08-22 | Kvartalsrapport 2011-Q2 |
| 2011-06-10 | Årsstämma 2011 |
| 2011-05-20 | Kvartalsrapport 2011-Q1 |
| 2011-02-24 | Bokslutskommuniké 2010 |
| 2010-11-24 | Kvartalsrapport 2010-Q3 |
| 2010-08-25 | Kvartalsrapport 2010-Q2 |
| 2010-05-28 | Ordinarie utdelning CLS B 0.00 SEK |
| 2010-05-26 | Kvartalsrapport 2010-Q1 |
| 2010-02-26 | Bokslutskommuniké 2009 |
| 2009-11-30 | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sweden - Today, February 14, 2024, Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that 189,182,414 new B-shares have been registered with the Swedish Companies Registration Office, as a result of the exercise of warrants of series TO 6 B ("TO 6 B").
Conversion of interim shares to ordinary B-shares takes place around February 21, 2024, and are expected to be available on each subscriber's account around February 23, 2024. The total number of shares in the Company as a result of the warrant exercise of TO 6 B and the directed new share issue to underwriters in connection with TO 6 B amount to 1,570,341,299, of which 600,000 A-shares and 1,569,741,299 B-shares, and the share capital will amount to approximately SEK 18,134,146.
Advisors
In connection with the exercise of warrants of series TO 6 B, Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent.
For more information about the warrants of series TO 6 B, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
Website: www.sedermera.se
Redeye AB
Phone: +46 (0)8 545 013 30
E-mail: info@redeye.se
Website: www.redeye.se
For more information about CLS, please contact:
Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
Website: www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se